ArticleNeuromolecular medicine2026
Sortilin is Associated with PGRN-Mediated Endoplasmic Reticulum Stress and Activation of Microglia in a Rat Model of Degenerative Cervical Myelopathy.
Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Degenerative cervical myelopathy (DCM) is a progressive spinal cord disorder primarily caused by chronic cervical compression. While Sortilin is implicated in degenerative and neuroinflammatory diseases, its specific role in DCM remains unclear. This study investigated the Sortilin-progranulin (PGRN) axis in DCM pathogenesis, and its potential association with endoplasmic reticulum (ER) stress, microglial activation and motor neuron injury. We established an in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model in BV2 microglia and an in vivo rat chronic compression DCM model. Sortilin expression was modulated via AAV-mediated shRNA knockdown (sh-Sortilin) or overexpression (OE-Sortilin) in vivo, and siRNA interference in vitro. We assessed cell viability, apoptosis and ROS production via CCK-8 and flow cytometry, performed immunofluorescence with quantitative Pearson’s correlation analysis, and examined neurological function, histopathology, apoptosis and microglial activation in DCM rats. Protein levels of ER stress markers, microglial activation markers and PGRN were detected by western blot, and serum pro-inflammatory cytokines via ELISA. Sortilin knockdown was associated with improved cell viability, as well as reduced apoptosis, ROS production, ER stress and pro-inflammatory activation in OGD/R-injured BV2 cells. PGRN knockdown reversed the protective effects of Sortilin silencing. In DCM rats, sh-Sortilin treatment was associated with improved neurological scores, reduced tissue damage and neuronal apoptosis, suppressed microglial activation and neuroinflammation, restored PGRN expression, and downregulated ER stress marker levels, while OE-Sortilin treatment showed opposite associations with DCM pathology and functional outcomes. In conclusion, the beneficial effects of Sortilin knockdown on DCM-related phenotypes are closely linked to PGRN, potentially via attenuating microglial ER stress and pro-inflammatory activation to protect spinal motor neurons.
Indexed as
Identifiers
42032174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.